{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-24-000117","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.280113+00:00","generated_at":"2026-05-30T08:58:20.486546+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiora receives IND approval for Phase 2 trial of KIO-301 in retinitis pigmentosa","bullets":["ABACUS-2 is a 36-patient, multi-center, double-masked, randomized, controlled Phase 2 trial.","Enrolling patients with ultra-low vision or no light perception regardless of gene mutation.","First patient dosing expected next year after validation of novel functional vision endpoints.","KIO-301 is a light-sensitive small molecule photoswitch targeting retinal ganglion cells.","Primary endpoints include safety, tolerability; key efficacy: functional vision and visual acuity tests."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-24-000117","json":"https://secwatch.observer/filing/0001372514-24-000117.json","markdown":"https://secwatch.observer/filing/0001372514-24-000117.md","text":"https://secwatch.observer/filing/0001372514-24-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000117/0001372514-24-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000117/kprx-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:58:20.486546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}